|Assessment Status||Awaiting full HTA submission from Applicant|
|Indication||For the treatment of adult patients with neovascular (wet) age-related macular degeneration.|
|Rapid review commissioned||29/08/2022|
|Rapid review completed||04/10/2022|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of faricimab compared with the current standard of care.*|
|Full pharmacoeconomic assessment commissioned by HSE||25/10/2022|
|Pre-submission consultation with Applicant||03/10/2023|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.